US EditionHims & Hers to Bring Generic Semaglutide to Canada
CANADA, JUL 8 – Aflivu is Apotex's first ophthalmic biosimilar and offers a cost-effective treatment option for multiple retinal diseases, supporting improved care for Canadian patients, officials said.
- Hims & Hers announced on Wednesday that it will offer a generic version of semaglutide in Canada, planning expansion by 2026.
- The expansion follows Ozempic's patent expiry on January 4, which opens the Canadian market for generic semaglutide by multiple manufacturers.
- Hims & Hers plans to offer affordable generic semaglutide by providing continuous access to licensed healthcare professionals and delivering personalized treatment at scale via its online services.
- Andrew Dudum emphasized their commitment to making the treatment widely available by offering affordable options alongside reliable, customized care on a large scale.
- This move may increase semaglutide demand and lower prices in Canada, where the 2024 market generated $1.18 billion in revenue.
Insights by Ground AI
Does this summary seem wrong?
16 Articles
16 Articles
All
Left
2
Center
4
Right
1
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels ...
SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s executives. Sookdeo v. Hims & Hers Health, Inc.,…
Hims & Hers to bring generic semaglutide to Canada
The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as Wegovy, will soon expire.
·Washington, United States
Read Full Article
Coverage Details
Total News Sources16
Leaning Left2Leaning Right1Center4Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 29%
C 57%
14%
Factuality
To view factuality data please Upgrade to Premium
